Immunovant jumps as $32 price-target hike revives IMVT-1402 focus
Immunovant shares rose about 5% as traders reacted to a fresh Wall Street price-target increase from $29 to $32 issued on April 15, 2026, while the firm kept a Neutral rating. The move appears momentum-driven after the April 2, 2026 Phase 3 batoclimab thyroid eye disease update refocused attention on the IMVT-1402 pipeline.
1) What’s moving the stock today
Immunovant (IMVT) traded higher Friday after a notable analyst update mid-week: a price-target increase to $32 from $29 dated April 15, 2026, while maintaining a Neutral/Hold stance. With no clearly disseminated same-day company press release or major SEC catalyst driving headlines, the action looks like a catch-up move to the revised valuation framework and broader positioning into upcoming pipeline milestones.
2) The bigger context investors are trading
The stock’s recent narrative has been shaped by Immunovant’s April 2, 2026 update on Phase 3 batoclimab in thyroid eye disease, which pulled attention back to portfolio strategy and the company’s longer-dated value driver, IMVT-1402. As the market digests what batoclimab can (and can’t) support commercially, investors have increasingly treated IMVT-1402 as the key program underpinning medium-term upside, making incremental changes in analyst models and targets more impactful.
3) What to watch next
Near-term trading may continue to be sensitive to additional model updates, conference commentary, and any new regulatory or trial-enrollment disclosures around IMVT-1402. Longer-term, the company’s timeline emphasizes potentially registrational development across multiple autoimmune indications, with major top-line readouts concentrated in 2027—meaning IMVT can see sharp moves on sentiment shifts well ahead of definitive data.